Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20797822 | 0.92 | PIK3CA (0.45) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL20797856 | 0.91 | HRH4 (0.51) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL30629327 | 0.91 | HRH4 (0.51) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL20797948 | 0.89 | PIK3CA (0.46) | ATRPIK3CAPIK3CDPIK3C3ATRIP | |
| SCHEMBL20798021 | 0.88 | PIK3CD (0.46) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL20798050 | 0.88 | ATR (0.44) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL738268 | 0.88 | PIK3CD (0.46) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL24173937 | 0.85 | ATR (0.48) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL20798055 | 0.85 | PIK3CA (0.44) | ATRPIK3CAPIK3CDPIK3C3PDCD1 | |
| SCHEMBL20797989 | 0.85 | ATR (0.48) | ATRPIK3CAPIK3CDPIK3C3PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655688-B | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3679041-B1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3679041-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2019050889-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | ATR 1/4885PIK3CA 702/4885PIK3CD 976/4885 |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | ATR, RB1, ATRIP | ATR 1/4885PIK3CA 702/4885PIK3CD 976/4885 |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | ATR 1/4885PIK3CA 702/4885PIK3CD 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.